Objective: We planned to examine the connection between serum uric acid (UA) values and prostatic calculi (PCal) presence and to evaluate the relation between PCal and other etiological factors. Methods: Patients between 20 and 60 years of age who were referred to the clinic with any reason and had non-contrast abdominal tomography (NCACT) for PCal were included in the study. While the patients were separated into 2 groups based on their serum UA level as ≥7 mg/dL (Group 1) and < 7 mg/dL (Group 2), NCACT was also divided into 2 groups as PCal presence (PCal+) and lack (PCal–) serum UA, calcium, phosphorus, sodium, prostate-specific antigen levels and urinary analysis results of the patients were evaluated and compared. Results: PCal were detected in 38 of 169 patients (22%). PCal presence was detected to be significantly high in Group 1 (p = 0.015). While Type A localization PCal were present both in Groups 1 and 2. Based on PCal presence, UA level was detected to be significantly high in PCal+ patients (p = 0.01). No significant difference was detected among the groups in biochemical parameters and urine-related parameters other than UA. Conclusion: A significant relation was found between high UA value and PCal in this study. These results may show that UA plays an active role in PCal etiology.

Keywords:
Prostatic calculi, Uric Acid, Calcium, Prostate-specific antigen, Urine PH
1.
Balasar M, Poyraz N, Göğer YE, Ünal Y, Pişkin MM: The incidence and location of prostatic calculi on noncontrast computed tomography images in patients with renal calculi. Urolithiasis 2015; 43: 375–378.
2.
Cao JJ, Huang W, Wu HS, Cao M, Zhang Y, Jin XD: Prostatic calculi: do they matter? Sex Med Rev 2018; 6: 482–491.
3.
Hyun JS: Clinical significance of prostatic calculi: a review. World J Mens Health 2018; 36: 15–21.
4.
Al-Taheini K, Filler G, Leonard M: Hypercalciuria associated with pediatric prostatic calculi. Can J Urol 2007; 14: 3577–3579.
5.
Engelhardt PF, Seklehner S, Brustmann H, Riedl CR, Lusuardi L: Association between asymptomatic inflammatory prostatitis NIH category IV and prostatic calcification in patients with obstructive benign prostatic hyperplasia. Minerva Urol Nefrol 2016; 68: 242–249.
6.
Kim WB, Doo SW, Yang WJ, Song YS: Influence of prostatic calculi on lower urinary tract symptoms in middle-aged men. Urology 2011; 78: 447–449.
7.
Park SW, Nam JK, Lee SD, Chung MK: Are prostatic calculi independent predictive factors of lower urinary tract symptoms? Asian J Androl 2010; 12: 221–226.
8.
Köseoğlu H, Aslan G, Sen BH, Tuna B, Yörükoğlu K: Prostatic calculi: silent stones. Acta Urol Esp 2010; 34: 555–559
9.
Dell’Atti L, Galosi AB, Ippolito C: Prostatic calculi detected in peripheral zone of the gland during a transrectal ultra sound biopsy can be significant predictors of prostate cancer. Arch Ital Urol Androl 2016; 88: 304–307.
10.
Lee SE, Ku JH, Park HK, Jeong CK, Kim SH: Prostatic calculi do not influence the level of serum prostate specific antigen in men without clinically detectable prostate cancer or prostatitis. J Urol 2003; 170: 745–748.
11.
Geramoutsos I, et al: Clinical correlation of prostatic lithiasis with chronic pelvic pain syndromes in young adults. Eur Urol 2004; 45: 333–337.
12.
Kirby RS, Lowe D, Bultitude MI, Shuttleworth KE: Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982; 54: 729–731.
13.
Tanaka Y, et al: The influence of serum uric acid on renal function in patients with calcium or uric acid stone: a population-based analysis. PLoS One 2017; 12:e0182136.
14.
Klimas R, Bennett B, Gardner WA Jr: Prostatic calculi: a review. Prostate 1985; 7: 91–96.
15.
Najoui M, Qarro A, Ammani A, Alami M: Giant prostatic calculi. Pan Afr Med J 2013; 14: 69.
16.
Wagner CA, Mohebbi N: Urinary pH and stone formation. J Nephrol 2010; 23(suppl 16): S165–S169.
17.
Umbehr MH, et al: Intraprostatic inflammation is positively associated with serum PSA in men with PSA < 4 ng mL (-1), normal DRE and negative for prostate cancer. Prostate Cancer Prostatic Dis 2015; 18: 264–269.
18.
Okada K, et al: Correlation of histological inflammation in needle biopsy specimens with serum prostate- specific antigen levels in men with negative biopsy for prostate cancer. Urology 2000; 55: 892–898.
19.
Kim SH, Jung KI, Koh JS, Min KO, Cho SY, Kim HW: Lower urinary tract symptoms in benign prostatic hyperplasia patients: orchestrated by chronic prostatic inflammation and prostatic calculi?. Urol Int 2013; 90: 144–149.
20.
Kucuk EV, Tahra A, BindayıA, Yıldırım U, Sobay R, Sen UT: The impact of prostate calcification on lower urinary tract symptoms. Androl Bul 2017; 19: 123–126.
21.
Khan A: Prevalence, pathophysiological mechanisms and factors affecting urolithiasis. Int Urol Nephrol 2018; 50: 799–806.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.